Area of research
Oncology · Cancer Research
Research interest
Research focused on Breast cancer and Oncology, with related work in Cancer, Ductal carcinoma, Cancer research. Notable publications include 'Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology', 'Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology', and 'Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology'.
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors
Breast Cancer, Version 3.2018
Expression of the BAD pathway is a marker of triple-negative status and poor outcome
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Breast Cancer Version 3.2014
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Metastatic Breast Cancer, Version 1.2012